Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category.
Atara Biotherapeutics Inc faces significant risk if it fails to identify and execute a viable strategic alternative or cannot raise the necessary capital for its operations. The board may have to consider a liquidation and dissolution, which would be heavily influenced by timing and the need to reserve cash for obligations, potentially leaving little for stockholders. Additionally, legal requirements under Delaware law necessitate settling outstanding and contingent liabilities before any shareholder distributions, further complicating the scenario. Consequently, investors could face a total loss if liquidation is pursued, underscoring the critical nature of the company’s strategic decisions.
Overall, Wall Street has a Hold consensus rating on ATRA stock based on 1 Buy and 3 Holds.
To learn more about Atara Biotherapeutics Inc’s risk factors, click here.